公开(公告)号：US10202325B2

公开(公告)日：2019-02-12

申请号：US16040281

申请日：2018-07-19

Applicant: BIOELECTRON TECHNOLOGY CORPORATION

Inventor： Paul Mollard

IPC: C07C46/06 ,  C07C403/08 ,  C07D311/72

Abstract: A method of producing alpha-tocotrienol quinone or a stereoisomer thereof, the method comprising selective opening of alpha-tocotrienol chroman to alpha-tocotrienol quinone in the presence of non-alpha tocotrienol chromans by oxidizing alpha-to-cotrienol with a metal salt oxidizing agent, wherein the stoichiometric ratio of metal salt oxidizing agent/alpha-tocotrienol is at least 4:1 and wherein said metal oxidizing agent is added in sequential additions, in order to reduce oxidation of any amounts of non-alpha tocotrienol chromans that might have been present in the starting alpha-tocotrienol chroman material. This process uses conditions favoring oxidation rates of the alpha tocotrienol chroman vs. the non-alpha tocotrienol chromans.

公开(公告)号：US10251847B2

公开(公告)日：2019-04-09

申请号：US15536603

申请日：2015-12-16

Applicant: BIOELECTRON TECHNOLOGY CORPORATION

Inventor： Paul Mollard ,  Christopher R. Cornell ,  Kieron E. Wesson ,  Peter Giannousis ,  Shazad Suchit ,  Mahmoud Mirmehrabi

IPC: C07C215/08 ,  C07C215/18 ,  C07C215/30 ,  C07C231/12 ,  C07C235/78 ,  A61K31/164 ,  A61K31/122 ,  C07C215/28 ,  C07B57/00

Abstract: Disclosed herein are polymorphic and amorphous forms of anhydrate, hydrate, and solvates of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide and methods of using such compositions for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging. Further disclosed are methods of making such polymorphic and amorphous forms.

公开(公告)号：US10167251B2

公开(公告)日：2019-01-01

申请号：US15374916

申请日：2016-12-09

Applicant: BioElectron Technology Corporation

Inventor： Orion D. Jankowski ,  Kieron E. Wesson ,  Paul Mollard ,  William D. Shrader

IPC: C07C235/80 ,  C07C235/78 ,  C07C317/28 ,  C07D207/27 ,  C07D211/46 ,  C07D213/40 ,  C07D233/61 ,  C07D295/13 ,  C07D295/192 ,  C07D265/30 ,  C07D311/66 ,  C07D207/26 ,  C07D213/50 ,  C07D295/116 ,  C07D295/185

Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, an well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

公开(公告)号：US09932286B2

公开(公告)日：2018-04-03

申请号：US14983330

申请日：2015-12-29

Applicant: BioElectron Technology Corporation

Inventor： Guy M. Miller ,  Sidney M. Hecht ,  Orion D. Jankowski ,  Kieron E. Wesson ,  Paul Mollard

IPC: C07C50/38 ,  C07C50/04 ,  A61K31/05 ,  A61K31/355 ,  C07C39/08 ,  C07C39/11 ,  C07C39/19 ,  C07C39/24 ,  C07C50/02 ,  C07C50/06 ,  C07C50/24 ,  C07C50/28 ,  C07C215/56 ,  C07C403/04 ,  C07C403/08 ,  C07C403/18 ,  C07C43/225 ,  C07C43/23 ,  C07C47/277 ,  C07C69/608 ,  C07C69/618 ,  C07C233/27 ,  C07C233/32 ,  C07C255/37

CPC classification number: C07C50/04 ,  A61K31/05 ,  A61K31/355 ,  C07C39/08 ,  C07C39/11 ,  C07C39/19 ,  C07C39/245 ,  C07C43/225 ,  C07C43/23 ,  C07C47/277 ,  C07C50/02 ,  C07C50/06 ,  C07C50/24 ,  C07C50/28 ,  C07C69/608 ,  C07C69/618 ,  C07C215/56 ,  C07C233/27 ,  C07C233/32 ,  C07C255/37 ,  C07C403/04 ,  C07C403/08 ,  C07C403/18 ,  C07C2601/16

Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

公开(公告)号：US20190270699A1

公开(公告)日：2019-09-05

申请号：US16228657

申请日：2018-12-20

Applicant: BIOELECTRON TECHNOLOGY CORPORATION

Inventor： Orion D. Jankowski ,  Kieron E. Wesson ,  Paul Mollard ,  William D. Shrader

IPC: C07C235/80 ,  C07C235/78 ,  C07C317/28 ,  A61P25/16 ,  A61P27/00 ,  A61P25/00 ,  C07C235/32 ,  A61P21/00 ,  C07D207/27 ,  C07D295/185 ,  C07D295/116 ,  C07D213/50 ,  C07D207/26 ,  C07D311/66 ,  C07D265/30 ,  C07D295/192 ,  C07D295/13 ,  C07D233/61 ,  C07D213/40 ,  C07D211/46

Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinoly)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

公开(公告)号：US10029971B2

公开(公告)日：2018-07-24

申请号：US15411861

申请日：2017-01-20

Applicant: BioElectron Technology Corporation

Inventor： Paul Mollard

IPC: C07C46/06 ,  C07C403/00 ,  C07D311/00

Abstract: A method of producing alpha-tocotrienol quinone or a stereoisomer thereof, the method comprising selective opening of alpha-tocotrienol chroman to alpha-tocotrienol quinone in the presence of non-alpha tocotrienol chromans by oxidizing alpha-tocotrienol with a metal salt oxidizing agent, wherein the stoichiometric ratio of metal salt oxidizing agent/alpha-tocotrienol is at least 4:1 and wherein said metal oxidizing agent is added in sequential additions, in order to reduce oxidation of any amounts of non-alpha tocotrienol chromans that might have been present in the starting alpha-tocotrienol chroman material. This process uses conditions favoring oxidation rates of the alpha tocotrienol chroman vs. the non-alpha tocotrienol chromans.

公开(公告)号：US20170297991A1

公开(公告)日：2017-10-19

申请号：US15411861

申请日：2017-01-20

Applicant: BioElectron Technology Corporation

Inventor： Paul Mollard

IPC: C07C46/06 ,  C07C2601/16

CPC classification number: C07C46/06 ,  C07C403/08 ,  C07C2601/16 ,  C07D311/72 ,  C07C50/28

Abstract: A method of producing alpha-tocotrienol quinone or a stereoisomer thereof, the method comprising selective opening of alpha-tocotrienol chroman to alpha-tocotrienol quinone in the presence of non-alpha tocotrienol chromans by oxidizing alpha-tocotrienol with a metal salt oxidizing agent, wherein the stoichiometric ratio of metal salt oxidizing agent/alpha-tocotrienol is at least 4:1 and wherein said metal oxidizing agent is added in sequential additions, in order to reduce oxidation of any amounts of non-alpha tocotrienol chromans that might have been present in the starting alpha-tocotrienol chroman material. This process uses conditions favoring oxidation rates of the alpha tocotrienol chroman vs. the non-alpha tocotrienol chromans.